Malaria vaccine
The present invention relates to a polypeptide consisting of an amino acid sequence selected from: (a) the amino acid sequence of SEQ ID NO: 4 or SEQ ID NO: 8, (b) an amino acid sequence that differs from the amino acid sequence of SEQ ID NO: 4 or SEQ ID NO: 8 by substitution, deletion, addition, or insertion of 1 to 10, preferably 1-5, more preferably 1, 2 or 3 amino acids, and (c) an amino acid sequence that has at least 95%, preferably 97%, more preferably 99% sequence identity with the amino acid sequence of SEQ ID NO: 4 or SEQ ID NO: 8, and a malaria vaccine comprising the polypeptide, for example.
1. A method of inhibiting growth of Plasmodium falciparum in a cell of a mammal, the method comprising administering to the mammal an immunogenic composition comprising a polypeptide consisting of
the amino acid sequence of SEQ ID NO: 4.
2. The method according to claim 1 , wherein the immunogenic composition further comprises, or is administered in combination with, at least one malaria vaccine antigen selected from circumsporozoite protein (CSP), thrombospondin-related anonymous protein (TRAP), merozoite surface protein-1 (MSP1), apical membrane antigen 1 (AMA-1), serine repeat antigen 5 (SERA5), GPI-anchored micronemal antigen (GAMA), erythrocyte binding antigen 175 (EBA175), reticulocyte-binding protein homologue 5 (RH5), Plasmodium falciparum surface protein 25 (Pfs25), and Plasmodium falciparum surface protein 230 (Pfs230).
3. The method according to claim 1 , wherein the immunogenic composition further comprises, or is administered in combination with, a vaccine antigen against at least one infectious disease selected from polio, diphtheria, pertussis, and tetanus.
4. The method according to claim 1 , wherein the method further comprises administering an adjuvant to the mammal.
5. A method of preventing development of malaria disease in a mammal having cells infected with P. falciparum , the method comprising administering to the mammal an immunogenic composition comprising a polypeptide consisting of the amino acid sequence of SEQ ID NO: 4.
6. The method according to claim 5 , wherein the immunogenic composition further comprises, or is administered in combination with, at least one malaria vaccine antigen selected from CSP, TRAP, MSP1, AMA-1, SERA5, GAMA, EBA175, RH5, Pfs25, and Pfs230.
7. The method according to claim 5 , wherein the immunogenic composition further comprises, or is administered in combination with, a vaccine antigen against at least one infectious disease selected from polio, diphtheria, pertussis, and tetanus.
8. The method according to claim 5 , wherein the method further comprises administering an adjuvant to the mammal.